BRIEF-Argenx To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod
Reuters Staff
1 Min Read
April 3 (Reuters) - ARGENX NV:
* TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)